Form 4: United Therapeutics CEO Executes Planned Stock Sale

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• Following the exercise, the CEO sold the 9,500 shares in multiple tranches at weighted average prices ranging from $561.21 to $567.41.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.
• The trading plan remains active until the earlier of December 31, 2026, or the exercise of 1,734,410 total options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the sale is a routine, pre-planned liquidity event by an executive and does not reflect a change in the company's fundamental outlook.

Positives

• The transaction was executed under a pre-arranged 10b5-1 plan, indicating the sale was scheduled in advance rather than based on non-public information.
• The CEO maintains a significant remaining beneficial ownership stake in the company, including direct and trust-held shares.

Negatives

• The sale represents a reduction in the CEO's direct equity holdings, though it is part of a long-term, pre-planned liquidity strategy.

Risks

• The ongoing 10b5-1 plan involves the potential sale of up to 1,734,410 shares, which could impact market liquidity or sentiment if executed in large volumes.

Future Outlook

The CEO's 10b5-1 plan is scheduled to continue through December 31, 2026, or until a total of 1,734,410 options are exercised, suggesting ongoing periodic sales of company stock.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are standard practice for long-tenured CEOs in the biotech sector to manage personal liquidity and diversify assets without triggering market concerns regarding insider sentiment.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate executives to ensure compliance with SEC regulations while liquidating equity compensation.
• The scale of the sale relative to the CEO's total holdings is consistent with typical executive wealth management strategies at large-cap pharmaceutical companies.

Related Party Transactions

• The reporting person holds shares in various family trusts where the reporting person or immediate family members are beneficiaries.

Stakeholder Impact

• Shareholders should view this as a planned liquidity event rather than a signal of management's outlook on the company's future performance.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, 10b5-1, Stock Options, Biotech